New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
12:27 EDTTWTR, GNW, NQ, REGN, HUM, DEST, RTOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday, with the Nasdaq leading and the Dow lagging, after a much better than expected reading on second quarter economic growth in the U.S. and ahead of a statement from the Federal Reserve following its latest policy meeting. With a solid earnings season and the economic data showing growth, investors are now on Fed watch, with the move in the averages potentially illustrating fear that the central bank may begin to get more hawkish. ECONOMIC EVENTS: In the U.S., the Commerce Department estimated that Gross Domestic Product grew at a seasonally adjusted annual rate of 4.0% in the second quarter, easily beating expectations for a growth rate of 3.0%. Payroll company ADP reported private payrolls climbed 218K in July, which was a bit below the 238K forecast. The Federal Reserve wraps up its two-day Federal Open Market Committee meeting today and the accompanying rate decision and statement is scheduled to be released at 2:00 pm ET. COMPANY NEWS: Shares of Twitter (TWTR) surged 20% higher after the social network operator's second quarter results beat analysts' consensus estimates and it raised its fiscal year 2014 revenue and adjusted EBITDA forecasts. Following last night's report, Bank of America Merrill Lynch upgraded Twitter to Buy from Neutral, while the stock was also upgraded to Outperform from Sector Perform at FBN Securities, to Neutral from Sell at UBS and to Market Perform from Underperform at Cowen. MAJOR MOVERS: Among the notable gainers was NQ Mobile (NQ), which jumped 15% to trade near $8 per share after the company reported it has received a non-binding proposal from Bison Capital to acquire all of NQ's outstanding American depositary shares for $9.80 each. Also higher was Regeneron (REGN), which rose 6% after the company announced that nine new Phase 3 Odyssey trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint. Among the noteworthy losers was Genworth Financial (GNW), which dropped 13% and was downgraded to Neutral from Outperform at Macquarie after its second quarter earnings report. Also lower following their earnings reports were Humana (HUM), which slid 5%, Ruby Tuesday (RT), which fell over 16%, and Destination Maternity (DEST), which dropped more than 19%. INDEXES: Near midday, the Dow was down 57.70, or 0.34%, to 16,854.41, the Nasdaq was up 9.01, or 0.2%, to 4,451.71, and the S&P 500 was down 3.87, or 0.2%, to 1,966.08.
News For TWTR;GNW;NQ;REGN;HUM;DEST;RT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 22, 2014
08:17 EDTGNWGenworth could rise more than 60% if split, Bloomberg says
Shares of Genworth Financial (GNW), which are trading below the price at which GE (GE) took it public in 2004, could rise 64% if it chose to separate its mortgage-guarantee operations from its life and long-term care insurance business, as has been suggested by shareholder John Paulson, estimates Bloomberg in its "Real M&A" column. Reference Link
07:29 EDTTWTRTwitter to hold annual conference
1st Annual Conference for Mobile Developers is being held in San Francisco on October 22.
06:06 EDTNQStocks with implied volatility above IV index mean; NQ TLM
Stocks with implied volatility above IV index mean; NQ Mobile (NQ) 178, Talisman Energy (TLM) 89 according to iVolatility.
October 21, 2014
16:00 EDTTWTROptions Update; October 21, 2014
Subscribe for More Information
11:41 EDTNQNQ Mobile 'not a stock for real investors,' Muddy Waters says
Muddy Waters said via Twitter that NQ Mobile is "not a stock for real investors, just pure gamblers."
10:00 EDTTWTROn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:37 EDTTWTRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR CVX VZ MCD GILD TXN
07:49 EDTTWTRTwitter October weekly volatility flat into developerís conference
Twitter October weekly call option implied volatility is at 51, November is at 67, December is at 58, January at 53; compared to its 26-week average of 54 according to Track Data, suggesting non-directional near term price movement into its developerís conference on October 22.
06:26 EDTNQStocks with implied volatility above IV index mean; NQ CMG
Subscribe for More Information
06:26 EDTTWTRTwitter expected to announce tools for app makers, WSJ reports
Twitter is expected to announce on Wednesday a suite of tools through an app-development platform called "Fabric" that will make it easier for programmers to build apps, sources tell the Wall Street Journal. The services are expected to address issues that affect mobile developers, like tracking analytics. Reference Link
06:09 EDTTWTRTwitter initiated with a Neutral at Citigroup
Subscribe for More Information
October 20, 2014
11:37 EDTTWTRStocks with call strike movement; X TWTR
Subscribe for More Information
07:16 EDTREGNAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
07:10 EDTREGNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:02 EDTREGNRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
October 17, 2014
16:01 EDTTWTROptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
12:17 EDTTWTRMark Cuban says buying Netflix shares, sees company as M&A target
Subscribe for More Information
09:38 EDTTWTRActive equity options trading on
Subscribe for More Information
09:06 EDTREGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
07:07 EDTREGNRegeneron announces EYLEA results from NIH study
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use